bioon.qiniudn.com/tm/UploadFiles/201507/2015070923441012.png" style="color: rgb(37, 37, 37); font-family: 微软雅黑, 'microsoft yahei', Arial, sans-serif; font-size: 16.470588684082px; line-height: 30px; text-indent: 2em; margin: 0px 0px 0px -2em; padding: 0px; border: none; max-width: 100%; height: auto;" alt="" />

-近日,来自瑞典的科学家通过对超过12.5万名孕妇进行研究发现,女性在怀孕期出现肝内胆汁淤积(intrahepatic cholestasis)相比非肝内胆汁淤积的孕妇而言,其在后期生活中将会存在患肝胆癌、免疫介导疾病及心血管疾病发病的风险,相关研究刊登于国际杂志the Journal of Hepatology上。

妊娠期肝内胆汁淤积症(Intrahepatic Cholestasis of Pregnancy,ICP)影响着大约0.4%-1.5%的妊娠女性,同时该病的主要特点为原因不明的瘙痒,同时伴随血清胆汁酸及肝脏酶类水平在妊娠末三个月和两个月升高,而这种疾病往往会增加孕妇早产以及频繁死产的风险;本文研究中研究者表示,ICP个体往往患肝胆癌及其它疾病的风险较高。

医学博士Hanns-Ulrich Marschall指出,对于ICP女性进行大量的人口研究调查表明ICP女性个体在后期生活中相比非ICP个体而言患肝脏癌症、免疫介导疾病及心血管疾病的风险较高。文章中研究者根据瑞典医学出生登记和瑞典病人登记的信息鉴别出了11388名患ICP的女性,以及113893名非ICP的女性个体,这些个体均在1973-2009年进行过生产,同时研究者对这些个体在生产前后的患癌及免疫疾病相关的信息进行了调查。

研究结果表明,相比非ICP个体而言,患ICP的个体患胆道系统癌症的风险是前者的2.5被,患肝脏癌症的风险是前者的3.5倍,在调整了因个体患丙肝而引发肝癌的情况后研究者仍然发现患ICP的个体患癌的风险是非ICP个体的2.5倍。研究者表示,ICP个体患多种免疫介导疾病的风险较高,比如相比非ICP个体而言患甲状腺疾病的风险会增加30%,糖尿病增加47%,银屑病风险增加27%,克罗恩氏病风险增加55%;同时研究者还发现ICP个体患心血管疾病的风险也会增加,但仅限于怀孕期间患ICP和先兆子痫的个体。

最后研究者表示,我们强烈建议ICP女性个体在生育后的6-12周进行血清肝脏检测,如果血清肝脏测试结果升高,那么就应该对女性个体的机体状况进行评估,来制定早期的疾病预防策略来保证其健康。

Effect of aerobic exercise training dose on liver fat and visceral adiposity

Shelley E. Keating, Daniel A. Hackett, Helen M. Parker, Helen T. O’Connor, James A. Gerofi, Amanda Sainsbury, Michael K. Baker, Vivienne H. Chuter, Ian D. Caterson, Jacob Georgecorrespondenceemail, Nathan A. Johnson

 

Background & Aims Aerobic exercise reduces liver fat and visceral adipose tissue (VAT). However, there is limited data from randomized trials to inform exercise programming recommendations. This study examined the efficacy of commonly prescribed exercise doses for reducing liver fat and VAT using a randomized placebo-controlled design. Methods Inactive and overweight/obese adults received 8?weeks of either; i) low to moderate intensity, high volume aerobic exercise (LO:HI, 50% VO2peak, 60?min, 4?d/week); ii) high intensity, low volume aerobic exercise (HI:LO, 70% VO2peak, 45?min, 3?d/week); iii) low to moderate intensity, low volume aerobic exercise (LO:LO, 50% VO2peak, 45?min, 3?d/week); or iv) placebo (PLA). Liver fat (spectroscopy) and VAT (magnetic resonance imaging) were measured before and after intervention. Results Forty-seven of the 48 (n?=?12 in each group) participants completed the trial. There were no serious adverse events. There was a significant change in group?×?time interaction in liver fat, which reduced in HI:LO by 2.38?±?0.73%, in LO:HI by 2.62?±?1.00%, and in LO:LO by 0.84?±?0.47% but not in PLA (increase of 1.10?±?0.62%) (p?=?0.04). There was a significant reduction in VAT in HI:LO (−258.38?±?87.78?cm3), in LO:HI (−386.80?±?119.5?cm3), and in LO:LO (−212.96?±?105.54?cm3), but not in PLA (92.64?±?83.46?cm3) (p?=?0.03). There were no significant differences between the dose or intensity of the exercise regimen and reductions in liver fat or VAT (p?>0.05). Conclusion The study found no difference in efficacy of liver fat reduction by either aerobic exercise dose or intensity. All of the aerobic exercise regimens employed reduced liver fat and VAT by a small amount without clinically significant weight loss.(来源:生物谷)